Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

nonacog beta pegol

- PMLiVE

Novo Nordisk: Tresiba makes a solid start

Long-acting insulin capturing share of diabetes market

- PMLiVE

Novo Nordisk chooses Mexico to launch urban diabetes plan

‘Cities Changing Diabetes’ partnership programme launches in Mexico City before global roll out

- PMLiVE

Novo Nordisk will build $100m facility in Denmark

Bagsvaerd site will support growing diabetes pipeline

- PMLiVE

Trial boost for Novo’s IDegLira ambitions

Company says drug shows weight benefits and low risk of hypoglycaemia

Bayer symbol

Bayer drug cuts infusion burden in haemophilia A

Able to provide longer-term protection against bleeding episodes in late-stage trial

- PMLiVE

Novo Nordisk names SVP biopharmaceuticals in US

Promotion for Eddie Williams

- PMLiVE

Novo partners with NHS on diabetes care

Danish pharma company will work with King’s Health Partners in South London

- PMLiVE

US approval for Novo’s Factor XIII drug Tretten

Becomes first recombinant treatment licensed for a rare clotting disorder

- PMLiVE

Police to probe Novo Nordisk over disclosure delay

Regulator says pharma company was late to announce FDA decision to not approve Tresiba and Ryzodeg

- PMLiVE

Study highlights poor diabetes consultation

Less than a third of patients asked for input into their treatment plans

Biogen Idec building

Biogen Idec’s haemophilia candidate faces US delay

FDA extends review of Alprolix

- PMLiVE

Novo enrols first patient in Tresiba cardiovascular trial

Milestone comes as diabetes-focused company reports solid growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links